View older revisions Content changed at 2023-07-30, 1402/05/08

Protocol summary

Study aim
Comparison of the effects of Rivaroxaban and Enoxaparin on the reduction of venous thromboembolism after spinal surgery
Design
A phase 3 Randomized clinical trial, with parallel group designed for 250 patients
Settings and conduct
Patients who underwent spine surgery at Imam Hossein Hospital in Tehran were included in the study to evaluate the effects of rivaroxaban and enoxaparin on reducing post operation deep vein thrombosis and venous embolism. All patients were evaluated after surgery for DVT and PTE by venous Doppler ultrasound and CT angiography of the lungs.
Participants/Inclusion and exclusion criteria
Patients who have undergone spine surgery and have no previous history of venous thromboembolism or cerebrovascular accident.
Intervention groups
Patients after spine surgery were divided into 3 groups, the group receiving Rivaroxaban, the group receiving Enoxaparin and the control group.
Main outcome variables
Deep vein thrombosis; Pulmonary thromboembolism

General information

Reason for update
Supplementary data from the clinical trial was recorded
Acronym
IRCT registration information
IRCT registration number: IRCT20200808048333N1
Registration date: 2021-10-29, 1400/08/07
Registration timing: registered_while_recruiting

Last update: 2023-07-30, 1402/05/08
Update count: 1
Registration date
2021-10-29, 1400/08/07
Registrant information
Name
Poorya Paryan
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 21 7343 0000
Email address
pooryaparyan@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2020-08-22, 1399/06/01
Expected recruitment end date
2021-07-21, 1400/04/30
Actual recruitment start date
2020-08-22, 1399/06/01
Actual recruitment end date
2022-12-13, 1401/09/22
Trial completion date
empty
Scientific title
Evaluation of the effect of Rivaroxaban and Enoxaparin on preventing the venous thromboembolism after spinal surgery
Public title
Comparison of Rivaroxaban and Enoxaparin for preventing venous thromboembolism after spine surgery
Purpose
Prevention
Inclusion/Exclusion criteria
Inclusion criteria:
Patients undergoing spine surgery No previous history of thromboembolism
Exclusion criteria:
Previous history of venous thromboembolism Pregnancy History of cerebrovascular accident
Age
From 18 years old
Gender
Both
Phase
3
Groups that have been masked
  • Participant
  • Care provider
  • Investigator
  • Outcome assessor
  • Data analyser
  • Data and Safety Monitoring Board
Sample size
Target sample size: 200
Actual sample size reached: 220
Randomization (investigator's opinion)
Randomized
Randomization description
the block randomization method will be used, and 11 blocks of 10 people will be created. Sealed Envelope online software will be used to create random codes. The number of patients in groups A and B in each block is equal, but the random sequence will differ.
Blinding (investigator's opinion)
Triple blinded
Blinding description
All Participants, Investigators, Outcome assessors, Data analyst, and quality controller are blinded. Due to the difference in the form of administration, the double dummy technique was used for blinding, as patients in the enoxaparin group received the injectable form of enoxaparin and placebo tablets, and the patients in the rivaroxaban group received the injectable form of placebo and rivaroxaban tablets.Placebo forms (both tablets and injectable forms) have the same shape, color and packaging as the original drug form.
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Shahid Beheshti University of Medical Sciences
Street address
Shahid Beheshti University of Medical Sciences, Kudakyar street, Shahid Shahriari Square, Daneshjou Boulevard, Shahid Chamran Highway
City
Tehran
Province
Tehran
Postal code
1983969411
Approval date
2020-11-10, 1399/08/20
Ethics committee reference number
IR.SBMU.MSP.REC.1399.411

Health conditions studied

1

Description of health condition studied
Deep Venous Thrombosis And Pulmonary Eembolism
ICD-10 code
I82.4
ICD-10 code description
Acute embolism and thrombosis of deep veins of lower extremity

Primary outcomes

1

Description
Deep Vein Thrombosis
Timepoint
At the begining of the study,14 days after
Method of measurement
Color Doppler Ultrasonography of the lower Extremities

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: Recipient of Rivaroxaban, patients that receive Rivaroxaban (10mg orally) once daily after surgery to prevent venous thromboembolism, until discharged from hospital.In this group, the effects of this drug on thromboembolic events after surgery will be investigated.
Category
Treatment - Drugs

2

Description
Intervention group: Recipient of Enoxaparin, patients that recieve Enoxaparin (40 mg subcutaneous ) once daily after surgery to prevent venous thromboembolism, until discharged from hospital.In this group, the effects of this drug on thromboembolic events after surgery will be investigated.
Category
Treatment - Drugs

3

Description
Control group: no medication
Category
N/A

Recruitment centers

1

Recruitment center
Name of recruitment center
Imam Hossein Hospital
Full name of responsible person
Hamidreza Khayat Kashani
Street address
Imam hosein hospital,Madani Ave,Nezamabad
City
Tehran
Province
Tehran
Postal code
1617763141
Phone
+98 21 7343 0000
Email
hamidkhayat@yahoo.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Afshin Zarghi
Street address
7th Floor, Bldg No.2 SBUMS, Arabi Ave, Daneshjoo Blvd, Velenjak, Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1983963113
Phone
+98 21 2243 9770
Email
Intl_office@sbmu.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Shahid Beheshti University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Hamidreza Khayat Kashani
Position
Associate Professor
Latest degree
Specialist
Other areas of specialty/work
Neurosurgery
Street address
Imam hosein hospital, Madani Ave, Nezamabad
City
Tehran
Province
Tehran
Postal code
1617763141
Phone
0098217343000
Email
hamidkhayat@yahoo.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Hamidreza Khayat Kashani
Position
Associate Professor
Latest degree
Specialist
Other areas of specialty/work
Neurosurgery
Street address
Imam hosein hospital, Madani Ave, Nezamabad
City
Tehran
Province
Tehran
Postal code
1617763141
Phone
0098217343000
Email
hamidkhayat@yahoo.com

Person responsible for updating data

Contact
Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Hamidreza Khayat Kashani
Position
Associate Professor
Latest degree
Specialist
Other areas of specialty/work
Neurosurgery
Street address
Imam hosein hospital, Madani Ave, Nezamabad
City
Tehran
Province
Tehran
Postal code
1617763141
Phone
0098217343000
Email
hamidkhayat@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Title and more details about the data/document
All data can be shared.
When the data will become available and for how long
Access period starts 6 months after the publication of the study
To whom data/document is available
Researchers working in academic and scientific institutions
Under which criteria data/document could be used
For scientific and academic studies
From where data/document is obtainable
Contact with Shahid beheshti university of medical sciences(info@sbmu.ac.ir) and Dr.hamidreza khayat kashani (hamidkhayat@yahoo.com).
What processes are involved for a request to access data/document
After approval from the University Vice Chancellor for Research, it is possible to share data.
Comments
Loading...